14th International Conference on Generic Drugs and Biosimilars
November 15-16, 2018 | Berlin, Germany
Best Western Premier Airporthotel Fontane Berlin
Theme: A new Era in Biosimilars Industry –Biosimilars & Generics
Conference series takes pleasure in inviting the scientific community across the globe to attend the 14th International Conference on Generic Drugs & Biosimilars during November 15-16, 2018 at Berlin, Germany with a motto to Explore Innovations in Biosimilars, Biologics, Generic drugs, Pharmaceutical Sciences, Pharma Industry, Drug delivery & Drug discovery.
The gathering will address Pharmaceutical & Biosimilar Research in the area of Pharmaceutical manufacturing, while laying emphasis on innovative methodologies in pharmaceutical and food manufacturing. Generic Biosimilars 2018 will be the best venue for Research Associate, Research Scientist, Directors, CEO’s of Pharmaceutical & Biosimilars Organizations, Drug Delivery Technology Manufacturers, Regulatory Affairs Associate, Bio Statistician, Health professionals, Scholars from Pharmaceutical backgrounds, Quality Control Analyst, Quality Assurance Specialist, Market research Analyst, Associate Product Manager, Product Manager, Strategy Director, Business Development Manager, Pharmacists, Deans, Students, Professors, Researchers, and Faculty of Pharmaceutical Sciences from Universities and Medical Colleges.
Keynote Speech: 1)The End of Phase 3 Clinical Trials in Biosimilars Development?
Francois-Xavier Frapaise, Principal, FX Frapaise Consulting, France

2)The importance of ensuring a sustainable market for Biosimilars
Erin Federman, Head of Biologics, Europe at Mylan

3)Workshop on: Biosimilars: Patient-Centricity
Francois-Xavier Frapaise, Principal, FX Frapaise Consulting, France

4)Pannel discussion on:
- Experience of Patient Advisory Boards
- Role of patients in protocol optimization ( ensuring the study protocols are feasible from a patient perspective)
- Patients Assistance Programs
- Patients education on Biosimilars
Francois-Xavier Frapaise, Principal, FX Frapaise Consulting, France

CONFERENCE HIGHLIGHTS
Generic drugs, generic pills and generic medication
Biosimilar and biologics
Pharmacovigilance and safety of biosimilars
Biosimilars uptake and patient safety
Generics and biosimilars industry strategy
Protein biotherapeutics and biosimilars
Developing biosimilars and biobetters
Biosimilar development challenges
Pharmacology and drug developement
Case study mitigating risk in biosimilar development
Quality control and R&D
Array of clinical trials in biosimilars
Patent access and intellectual property and FDA regulations
Pharma pricing and market access
Licensing, manufacturing and health economics
Chronicles of biosimilar production facility
Global generic trends and global pharma market
Innovation and technology for biosimilar development
Biosimilars differentiated through novel drug delivery technologies
GMP, GCP and quality control
Office of generic drugs (OGD)
Entrepreneurs investment meet

Generic Biosimilars 2018 is comprised of 22 tracks and 110 sessions designed to offer comprehensive sessions that address current issue. For more scientific sessions and abstract submission, please visit:
https://generic-market.pharmaceuticalconferences.com/

The Abstracts that are accepted for presentations are published in the proceedings of the Journals like Journal of Developing Drugs, Drug Designing: Open Access and Journal of Bioequivalence & Bioavailability.

Grab the opportunity to participate by registering through flowing link:
https://generic-market.pharmaceuticalconferences.com/registration.php

For further details, please contact:
Regards
Missy Christen | Program Manager
Generic Biosimilars 2018
47 Churchfield Road
London, W3 6AY, UK
Direct: (702) 508-5200 Ext: 8028
E: genericpharma@pharmaceuticalconferences.org

• Share
• Tweet